New drugs approved in 2010
Erin Sears, PharmD, and Tegan Steimel Th is article briefl y reviews select new drug entities approved by the Food and Drug Administration in 2010.
CARGLUMIC ACID (CARBAGLU)
Th erapeutic use: Carglumic acid (1), a structural analog of N-acetylglutamate (NAG), is an allosteric activator of carbamoyl phosphate synthetase 1 (CPS 1) in liver mitochondria. NAG is the product of NAG synthase, a mitochondrial enzyme; CPS 1 is the fi rst enzyme of the urea cycle, which converts ammonia into urea. Carglumic acid acts as a replacement for NAG in patients with NAG synthase defi ciency by activating CPS 1. It is indicated for both acute and chronic hyperammonemia due to the defi ciency of the hepatic enzyme NAG synthase.
Recommended dosage: Th e recommended initial dose for acute hyperammonemia is 100 to 250 mg/kg/day rounded to the nearest 100 mg and divided into 2 to 4 doses. Concomitant administration of other ammonia-lowering therapies is recommended. Dosing should be titrated based on individual patient plasma ammonia levels and clinical symptoms. Tablets should not be swallowed whole or crushed; each tablet should be dispersed in a minimum of 2.5 mL of water and taken immediately. Carglumic acid is available as 200-mg tablets.
Drug interactions: No drug interaction studies have been performed.
Adverse reactions: Eff ects most commonly associated with therapy include vomiting, abdominal pain, pyrexia, tonsillitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.
Other comments: Treatment with carglumic acid should be initiated by a physician experienced in metabolic disorders. Before opening the bottle, tablets should be refrigerated at 2 o to 8 o C; after opening the bottle, tablets should be kept at room temperature labeled with an expiration of 1 month.
CEFTAROLINE (TEFLARO)
Th erapeutic use: Ceftaroline fosamil (2-6) is a cephalosporin antibacterial prodrug approved for the treatment of acute bacterial skin and skin structure infections (SSSIs) and communityacquired bacterial pneumonia in adults. Ceftaroline is the fi rst cephalosporin active against resistant gram-positive pathogens. Ceftaroline is indicated to treat SSSIs caused by susceptible isolates of the following microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Escherichia coli, Klebsiella pneumoniae, and K. oxytoca. Ceftaroline covers susceptible isolates of the following microorganisms that may cause community-acquired pneumonia: Streptococcus pneumoniae (including cases with concurrent bacteremia), Staphylococcus aureus (methicillin-susceptible isolates only), Haemophilus infl uenzae, K. pneumoniae, K. oxytoca, and E. coli. Ceftaroline's activity against methicillin-resistant Staphylococcus aureus is attributed to its high-affi nity binding to penicillin-binding protein (PBP) 2a and more effi cient inhibition of the biochemical activity of PBP 2a than β-lactams currently available.
Recommended dosage: Th e recommended dose of ceftaroline is 600 mg administered intravenously over 1 hour every 12 hours. Th e recommended treatment duration is 5 to 14 days for SSSIs and 5 to 7 days for community-acquired pneumonia; however, therapy duration should be individualized based on severity, site of infection, and the patient's clinical and bacteriological progress. Dosing should also be individualized based on renal function (Table 1) . Ceftaroline is available as powder for reconstitution in 400-mg and 600-mg vials. Drug interactions: Th e use of ceftaroline with other drugs has not been extensively studied.
Adverse reactions: Th e most common adverse reactions associated with ceftaroline are diarrhea, nausea, and rash. As with other cephalosporins, patients using ceftaroline are at risk for the development of an anaphylactic reaction and Clostridium diffi cile-associated diarrhea.
Other comments: Seroconversion from a negative to a positive direct Coombs' test result occurred in approximately 10% of the phase 3 study population. If anemia develops during or after treatment with ceftaroline, drug-induced hemolytic anemia should be ruled out.
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (XIAFLEX)
Th erapeutic use: Collagenase clostridium histolyticum (7, 8) is indicated for the treatment of Dupuytren's contracture with a palpable cord in adults. Dupuytren's disease is a fi broproliferative disorder of unknown etiology aff ecting the hand that often results in shortening and thickening of the palmar fascia, leading to permanent and irreversible fl exion contracture of the digits. Collagenases are proteinases that are able to hydrolyze collagen in its native conformation under physiological conditions, resulting in lysis of collagen deposits. Injection of collagenase clostridium histolyticum into a Dupuytren's cord, which is composed mostly of collagen, may result in enzymatic disruption of the cord and contracture relief.
Recommended dosage: Collagenase clostridium histolyticum is dosed at 0.58 mg per injection, with the powder reconstituted using diff ering volumes of diluents based on whether the aff ected joint is a metacarpophalangeal joint or a proximal interphalangeal joint. Approximately 24 hours after injection, a fi nger extension procedure should be performed to facilitate cord disruption; if after 4 weeks the contracture remains, the cord may be reinjected with collagenase and the fi nger extension procedure may be repeated. Collagenase clostridium histolyticum is available as lyophilized powder in a 0.9-mg vial, which is accompanied by the sterile diluent to be used for reconstitution.
Drug interactions: Cautious use of injectable collagenase in patients who have received anticoagulants or platelet inhibitors (except aspirin up to 150 mg daily) is required, as effi cacy and safety with concomitant use is unknown. With no detectable levels of injectable collagenase in plasma for up to 30 days after administration, other interactions are unlikely.
Adverse reactions: Th e most common adverse eff ects associated with the use of collagenase clostridium histolyticum include swelling of the injected hand, contusion, injection site reaction, injection site hemorrhage, and pain in the injection site hand. Injection of collagenase into collagen-containing structures such as tendons or ligaments of the hand may result in damage to those structures and possible permanent injury, such as tendon rupture or ligament damage. Th erefore, collagenase should be injected only into the collagen cord, and care should be taken to avoid injecting it into tendons, nerves, blood vessels, or other collagen-containing structures of the hand.
Additionally, anaphylaxis is a potential reaction that health care providers should be prepared to treat.
Other comments: Collagenase clostridium histolyticum should be administered by a health care provider experienced in injection procedures of the hand and in the treatment of patients with Dupuytren's contracture. Th e reconstituted collagenase solution may be kept at room temperature for up to 1 hour or refrigerated at 2° to 8°C for up to 4 hours; the product should be at room temperature for administration.
DABIGATRAN (PRADAXA)
Th erapeutic use: Th e direct thrombin inhibitor dabigatran (9, 10) is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fi brillation. Th rombin enables the conversion of fi brinogen into fi brin in the coagulation cascade; inhibition of thrombin helps to prevent the development of a thrombus. Dabigatran is able to eff ectively inhibit both free and clot-bound thrombin and thrombin-induced platelet aggregation. Dabigatran is one of two orally available anticoagulants, the other being warfarin. Warfarin has a narrow therapeutic index, requiring intensive monitoring, and has extensive drug-drug and drug-food interactions. Dabigatran has fewer drug-drug interactions and does not require intensive monitoring; however, there is no specifi c antidote for dabigatran in patients who may experience major bleeding.
Recommended dosage: Dabigatran should be dosed at 150 mg twice daily. Dosage adjustment is required in renal impairment; patients with a creatinine clearance of 15 to 30 mL/min should receive 75 mg twice daily. When converting from a parenteral anticoagulant to dabigatran, bridge therapy is not necessary; dabigatran should be started 0 to 2 hours before the time that the next dose of the parenteral drug was to have been administered or at the time of discontinuation of a continuously administered parenteral drug. Dabigatran is available as 75-mg capsules.
Drug interactions: Dabigatran is a substrate of P-glycoprotein (P-gp); plasma concentrations of dabigatran may be aff ected by inhibitors or inducers of P-gp. Concomitant use with P-gp inducers (specifi cally rifampin) should be avoided. In general, concomitant use with P-gp inhibitors does not require dose adjustments. Use with other anticoagulants or thrombolytic agents leads to an increased risk of bleeding.
Adverse reactions: Gastritis-like symptoms and bleeding are the most common adverse reactions. Dabigatran is contraindicated in patients with active bleeding.
Other comments: When possible, dabigatran should be temporarily discontinued before invasive surgical procedures and then promptly restarted afterwards.
DALFAMPRIDINE (AMPYRA)
Th erapeutic use: Th e potassium channel blocker dalfampridine (11) is used to improve walking, measured by walking speed, in patients with multiple sclerosis (MS). Th e percentage of dalfampridine recipients with at least a 10%, 20%, or 30% increase in walking speed from baseline was signifi cantly higher compared with placebo recipients.
Recommended dosage: Th e recommended and maximum dose of dalfampridine is 10 mg twice daily with or without food. Dalfampridine is contraindicated in patients with a creatinine clearance of ≤50 mL/min. It is available as a 10-mg tablet.
Drug interactions: No signifi cant drug interactions with dalfampridine have been identifi ed. In vitro, dalfampridine is not an inducer or inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4/5. Dalfampridine is not likely to aff ect the pharmacokinetics of drugs that are substrates of these enzymes. Further, dalfampridine is neither a substrate nor an inhibitor of P-gp.
Adverse reactions: Th e most common adverse reactions MS patients experience with dalfampridine treatment include urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, MS relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain. At doses of 20 mg twice daily, an increased incidence of seizures was noted; dalfampridine is contraindicated in patients with a history of seizures.
DENOSUMAB (PROLIA, XGEVA)
Th erapeutic use: Denosumab (12, 13) is a monoclonal antibody directed against the receptor activator of nuclear factor kappa-beta ligand (RANKL). Denosumab prevents RANKL from activating its receptor, RANK, on osteoclast surfaces and their precursors. Prevention of this interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone. Denosumab has been approved under the brand name Prolia for the treatment of postmenopausal women with osteoporosis at high risk for fracture and under the brand name Xgeva for the prevention of skeletal-related events in patients with bone metastases from solid tumors.
Recommended dosage: Prolia is supplied as a 1-mL prefi lled syringe containing a solution of 60 mg/mL to be administered subcutaneously every 6 months in the specifi ed patient population. Xgeva is supplied as a 1.7-mL prefi lled syringe containing 70 mg/mL (120 mg/syringe) to be administered subcutaneously every 4 weeks in the specifi ed patient population.
Drug interactions: Th ere have been no formal studies regarding drug-drug interactions with denosumab.
Adverse reactions: Th e most common adverse reactions involving denosumab include back pain, extremity pain, hypercholesterolemia, musculoskeletal pain, and cystitis. More severe events that have been associated with denosumab use include hypocalcemia, infection, dermatological reaction, osteonecrosis of the jaw, and oversuppression of bone turnover. Patients taking denosumab should be instructed to take 1000 mg of calcium daily and at least 400 IU vitamin D daily to avoid hypocalcemia.
Other comments: Denosumab should be protected from light and refrigerated (2° to 8°C) prior to use. Th e product must be used within 14 days after removal from refrigeration.
HYDROMORPHONE EXTENDED RELEASE (EXALGO)
Th erapeutic use: Exalgo is an extended-release oral formulation of hydromorphone (14) indicated for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. Patients are considered opioid tolerant if they are taking at least 60 mg oral morphine/day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for a week or longer. Exalgo is not intended for use as an as-needed analgesic or in the management of acute or postoperative pain.
Recommended dosage: When initiating treatment with Exalgo, health care providers need to consider the daily dose, potency, and specifi c characteristics of the opioid the patient had previously been taking, as well as the patient's degree of opioid tolerance, age, general condition, and medical status. Th is new extended-release formulation of hydromorphone is available as 8-mg, 12-mg, and 16-mg tablets. Table 2 shows the conversion from the current oral opioid therapy to hydromorphone.
Drug interactions: As with other opioid analgesics, Exalgo is not recommended to be used in combination with other central nervous system depressants (including alcohol), monoamine oxidase inhibitors, or opioid antagonists. Concomitant use with anticholinergics could lead to an increased risk of urinary retention and severe constipation, which may lead to paralytic ileus. Additionally, data suggest that hydromorphone in clinically relevant concentrations does have a minimal potential to inhibit the activity of human hepatic CYP450 enzymes including CYP1A2, 2C9, 2C19, 2D6, 3A4, and 4A11; care should be taken, as Exalgo may increase concentrations of drugs metabolized via the aforementioned enzymatic pathways.
Black box warning: Hydromorphone has a high potential for abuse and is classifi ed as a schedule II controlled substance. Exalgo is only to be used in opioid-tolerant patients due to the high risk of fatal respiratory depression in an overdose situation. Tablets should be swallowed whole to allow for slow release and absorption of hydromorphone. Accidental consumption may lead to fatal overdose, especially in children.
Adverse reactions: Consistent with others in its class, hydromorphone's adverse eff ects include respiratory depression, hypotensive eff ects, gastrointestinal eff ects, cardiac arrest, head injury, and increased intracranial pressure. Other comments: Exalgo is contraindicated in opioid nontolerant patients, patients with impaired pulmonary function, and patients with paralytic ileus.
LIRAGLUTIDE (VICTOZA)
Th erapeutic use: Liraglutide (15) (16) (17) (18) (19) is an incretin mimetic that acts as an agonist at the glucagon-like-peptide-1 (GLP-1) receptor; it is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Four 26-week trials with liraglutide as add-on therapy have been conducted; treatment protocols included liraglutide in combination with metformin, glimepiride, metformin plus glimepiride, and metformin plus rosiglitazone. In each of these trials, treatment with liraglutide resulted in improvements to hemoglobin A1C and fasting plasma glucose when compared with placebo. In addition, liraglutide given in combination with certain medications may contribute to weight loss.
Recommended dosage: Initial dosing should be 0.6 mg per day for 1 week to reduce gastrointestinal symptoms; this dose is not eff ective for glycemic control. Th e dose should be increased to 1.2 mg per day and can be increased further to 1.8 mg per day to achieve acceptable glycemic control. Liraglutide should be administered subcutaneously in the abdomen, thigh, or upper arm and can be given at any time during the day, independent of meals. Liraglutide is supplied in a prefi lled pen as an 18 mg/3 mL solution for injection.
Drug interactions: Liraglutide causes a delay of gastric emptying and thus has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, liraglutide did not aff ect the absorption of the tested orally administered medications to any clinically relevant degree. Serious hypoglycemia can occur when liraglutide is used with a sulfonylurea; the sulfonylurea dose may need to be lowered upon initiation of liraglutide.
Black box warning: Liraglutide causes thyroid C-cell tumors at clinically relevant exposures in rodents; the existence of similar eff ects in humans is still unknown. Use of liraglutide in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2 is contraindicated.
Adverse reactions: Th e most common adverse reactions are headache, nausea, diarrhea, and anti-liraglutide antibody formation. In clinical trials, more cases of pancreatitis occurred among patients receiving liraglutide than comparators. If pancreatitis is suspected, liraglutide should be discontinued.
Other comments: Liraglutide should be stored in the refrigerator (2° to 8°C) until fi rst use. After fi rst use it has a beyonduse date of 30 days, either refrigerated or at room temperature (15° to 30°C). Liraglutide should be protected from extreme temperatures and sunlight.
LURASIDONE (LATUDA)
Th erapeutic use: Th e atypical antipsychotic lurasidone (20) is approved for use in schizophrenia. Although the exact mechanism of lurasidone has not been determined, modulation of central dopaminergic and serotonergic activity is thought to be the mechanism by which atypical antipsychotics are able to reduce the positive and negative symptoms of schizophrenia.
Recommended dosage: Th e recommended dose is 40 mg once daily, with a maximum daily dose of 80 mg. Lurasidone should be taken with food. It is available as 40-mg and 80-mg tablets.
Drug interactions: Lurasidone is highly protein bound and is metabolized primarily via the CYP3A4 pathway. Concomitant administration with either strong inducers (e.g., rifampin) or inhibitors (e.g., ketoconazole) of CYP3A4 is contraindicated.
Black box warning: Due to the increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack) seen in elderly patients with dementia-related psychoses treated with atypical antipsychotic drugs, lurasidone is not approved for the treatment of patients with dementia-related psychosis. Studies indicate that elderly patients with dementiarelated psychosis treated with antipsychotic drugs are at an increased risk of death.
Adverse reactions: Common adverse reactions include somnolence, akathisia, nausea, parkinsonism, and agitation. Th e following adverse events are possible with all atypical antipsychotics, including lurasidone, and should be managed and monitored as clinically appropriate: neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, hyperglycemia and diabetes mellitus, dyslipidemia, weight gain, hyperprolactinemia, leukopenia, neutropenia, agranulocytosis, orthostatic hypotension and syncope, seizures, and potential for cognitive and motor impairment.
Other comments: Lurasidone should be taken with a minimum of 350 calories of food.
PEGLOTICASE (KRYSTEXXA)
Th erapeutic use: Pegloticase (21-23) is a pegylated enzyme specifi c for uric acid. It is approved for use in patients with chronic gout refractory to other treatments. Pegloticase decreases uric acid concentrations by converting uric acid into allantoin, a benign metabolite that is easily excreted in the urine. Unfortunately, anti-pegloticase antibody development is high with use of pegloticase, and infusion reactions and hypersensitivity may limit use.
Recommended dosage: Th e recommended dosing for adults is 8 mg, given as an intravenous infusion every 2 weeks. Pegloticase should only be administered by intravenous infusion over no less than 120 minutes via gravity feed, syringe-type pump, or infusion pump. Pegloticase is supplied as a 1-mL sterile concentrate for dilution containing 8 mg of pegloticase protein, expressed in uricase protein amounts.
Drug interactions: No drug interaction studies have been performed. Anti-pegloticase antibodies appear to bind to the PEG portion of the drug; thus, the potential for binding with other pegylated products exists. Th e clinical implications are currently unknown.
Black box warning: Anaphylaxis and infusion reactions have been reported to occur during and after administration of pegloticase; therefore, the drug should only be administered in a health care setting by a health care provider equipped to handle such reactions.
Adverse reactions: Th e most common adverse reactions are gout fl ares, infusion reactions, nausea, contusion or ecchymosis, nasopharyngitis, constipation, chest pain, anaphylaxis, and vomiting. In premarketing clinical trials, anaphylaxis occurred in 6.5% of patients treated with pegloticase 8 mg every 2 weeks compared to none of the placebo patients, and infusion reactions occurred in 26% vs 5%, respectively.
Other comments: Use of pegloticase is not recommended for the treatment of asymptomatic hyperuricemia. Patients receiving pegloticase should be pretreated with an antihistamine and corticosteroid. Pegloticase should be stored in the carton and maintained under refrigeration between 2° to 8°C prior to preparation. Th e product should be protected from light, agitation, and freezing temperatures.
TESAMORELIN (EGRIFTA)
Th erapeutic use: Th e growth hormone releasing factor tesamorelin (24-28) is indicated for lipodystrophy in HIVinfected patients. Lipodystrophy is characterized by adipose tissue redistribution and certain metabolic disorders including hypercholesterolemia and insulin resistance. Long-term highly active antiretroviral therapy exposure, particularly the combination of lopinavir and ritonavir, has the potential to lead to the development of dyslipidemia and lipodystrophy syndrome.
Recommended dosage: Recommended dosing for tesamorelin is 2 mg injected subcutaneously once daily. Tesamorelin is supplied in a kit for subcutaneous injection containing 1-mg vials of tesamorelin and additional vials containing the reconstitution diluents (sterile water for injection). Th e drug should be injected into the skin of the abdomen.
Drug interactions: Data suggest that growth hormone may alter the clearance of cytochrome P450-metabolized drugs; since tesamorelin stimulates growth hormone, patients receiving tesamorelin and compounds metabolized by CYP450 should be carefully monitored. Also, patients receiving glucocorticoids may require increased maintenance or stress dosages after initiation of tesamorelin.
Adverse reactions: Th e most commonly reported adverse reactions associated with tesamorelin are arthralgia, injection site erythema, injection site pruritus, extremity pain, peripheral edema, and myalgia.
Other comments: Th e reconstituted tesamorelin solution should be injected immediately. Nonreconstituted vials should be stored in the refrigerator (between 2° and 8°C) and protected from light. Th e reconstitution diluents should be stored at room temperature.
TOCILIZUMAB (ACTEMRA)
Th erapeutic use: Tocilizumab (29) is an interleukin-6 (IL-6) inhibitor indicated for the treatment of rheumatoid arthritis in patients in whom one or more tumor necrosis factor inhibitors have failed. Tocilizumab exerts its eff ects in the serum and synovial fl uid, where elevated IL-6 concentrations tend to occur in patients with rheumatoid arthritis. Additionally, elevated IL-6 concentrations are associated with disease activity and joint damage. Tocilizumab can be given independently or concomitantly with methotrexate or other disease-modifying antirheumatic drugs.
Recommended dosage: Initial dosing for tocilizumab is 4 mg/kg given as a 1-hour intravenous infusion every 4 weeks. Th e dose may be increased, based on response to 8 mg/kg intravenously every 4 weeks. Doses >800 mg per infusion are not recommended. Tocilizumab is available as single-use vials in the following strengths: 80 mg/4 mL, 200 mg/10 mL, and 400 mg/20 mL. Tocilizumab dosing should be adjusted as a result of certain dose-related laboratory changes; see Table 3 for a summary.
Drug interactions: Tocilizumab has the potential to aff ect expression of multiple CYP enzymes. Th e formation of CYP450 enzymes may be suppressed by increased concentrations of cytokines such as IL-6 during chronic infl ammation; as an IL-6 inhibitor, tocilizumab is expected to normalize the formation of these CYP450 enzymes. Care should be taken when using tocilizumab in combination with CYP3A4 substrate drugs. Adverse reactions: Th e most common adverse reactions associated with tocilizumab include upper respiratory tract infections, nasopharyngitis, headache, hypertension, and increased alanine transaminase levels.
Other comments: Tocilizumab should not be administered if the patient is experiencing an active infection, including a localized infection. Tocilizumab must be refrigerated and not frozen. Vials must be protected from light by storage in their original package until time of use.
VELAGLUCERASE ALFA (VPRIV)
Th erapeutic use: Velaglucerase alfa (30-32) is a hydrolytic lysosomal glucocerebroside-specifi c enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease. Gaucher disease is caused by a defi ciency of glucocerebrosidase, which helps the body metabolize glucocerebroside, a fatty material. Glucocerebroside can build up to harmful levels in the liver, spleen, lungs, bone marrow, and brain. Th is accumulation of fatty material in tissues interferes with the normal functioning of the body's organs and may cause organ enlargement and bone pain. Velaglucerase alfa is produced by gene activation technology in a human fi broblast cell line and, unlike current glucocerebrosidase moieties, has the same amino acid sequence as the naturally occurring human enzyme. Th e safety and effi cacy of velaglucerase alfa have been established in children 4 years and older.
Recommended dosage: Velaglucerase should be dosed at 60 units/kg infused intravenously over 60 minutes every other week. Dosage adjustments, more specifi cally decreases in dose, can be made based on achievement and maintenance of each patient's therapeutic goals. Velaglucerase is supplied as a lyophilized powder to be reconstituted and diluted for infusion; it is available in 200-unit and 400-unit single-use vials.
Drug interactions: No studies have been done regarding drug-drug interactions with velaglucerase.
Adverse reactions: Th e most common adverse reactions associated with velaglucerase are infusion-related reactions (i.e., headache, dizziness, abdominal pain, nausea, back pain, joint pain, upper respiratory tract infection, prolongation of activated partial thromboplastin time, fatigue/asthenia, and pyrexia). Additionally, hypersensitivity can occur with velaglucerase alfa, and care should be exercised.
Other comments: Velaglucerase should be stored protected from light in a refrigerator at 2° to 8°C. Reconstituted velaglucerase should be used immediately. If immediate use is not possible, the product may be stored for up to 24 hours in a refrigerated location. Table 4 provides information regarding new chemotherapeutic agents and their approved indications. Eribulin mesylate Halaven Treatment of metastatic breast cancer in patients who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
CHEMOTHERAPEUTIC AGENTS

Sipuleucel-T Provenge
Treatment of asymptomatic or minimally symptomatic metastatic hormone-refractory prostate cancer.
*From product information (33) (34) (35) .
